IP Library Granted Patent US 10,101,310
Granted Patent B2
US 10,101,310 · App. 15/426,206 · Granted Oct 16, 2018

Potency test for vaccine formulations

Inventors: Michelle Allen (DeSoto, KS); Mark Garrett (Overland Parks, KS); Urs Peter Bruderer (Kleve, DE); Martinus Antonius Johannes Thijssen (Groeningen, NL)
Assignee: Intervet Inc.
G01N33/15G01N33/56933G01N33/56983G01N2333/01G01N2333/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,101,310
App. No.
15/426,206
Granted
Oct 16, 2018
Kind
B2
Abstract

The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.

Claims (7)

1. A method for the determination of an antigen content of a first antigen in a mixture of at least a composition comprising the first antigen and a composition comprising a second antigen, the method comprising the steps of:

a) separating the second antigen from antibodies that are capable of binding with the first antigen in a composition comprising the second antigen and the antibodies;

b) mixing the second antigen with a composition comprising the first antigen; and

c) determining the antigen content of the first antigen in the mixture by means of an immunoassay; wherein the first antigen is a PCV-2 antigen and the second antigen is a Mycoplasma hyopneumoniae ( M. hyo ) antigen.

2. The method of claim 1 , wherein the method is a potency test of a combination vaccine.

3. The method of claim 1 , wherein the PCV-2 antigen is a PCV-2 ORF2 protein and the M. hyo antigen is a bacterin.

4. The method of claim 3 , wherein the method is a potency test of a combination vaccine.

Assignments (4)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2018
From: ALLEN, MICHELLE; GARRETT, MARK
To: INTERVET INC.
Reel/Frame 046790/0226 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2018
From: BRUDERER, URS PETER; THIJSSEN, MARTINUS ANTONIUS JOHANNES
To: INTERVET INTERNATIONAL B.V.
Reel/Frame 046790/0419 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2018
From: INTERVET INTERNATIONAL B.V.
To: INTERVET INC.
Reel/Frame 046790/0496 →
Continuity (5)
Division 14320840 · Jul 1, 2014
Division 13759620 · Feb 5, 2013
Continuation 12875618 · Sep 3, 2010
Provisional Application 61377485 · Aug 27, 2010
Related Publication 20170146506A1 · May 25, 2017